BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E25.25 EPS (ttm)2.95 Insider Own0.07% Shs Outstand2.13B Perf Week2.57%
Market Cap154.87B Forward P/E9.10 EPS next Y8.19 Insider Trans-17.54% Shs Float2.12B Perf Month2.08%
Income6.33B PEG6.62 EPS next Q1.99 Inst Own79.40% Short Float / Ratio0.99% / 2.33 Perf Quarter-5.41%
Sales46.16B P/S3.36 EPS this Y178.00% Inst Trans-0.72% Short Interest20.96M Perf Half Y0.98%
Book/sh15.32 P/B4.86 EPS next Y1.92% ROA6.40% Target Price82.49 Perf Year14.66%
Cash/sh4.34 P/C17.16 EPS next 5Y3.82% ROE19.90% 52W Range65.00 - 81.43 Perf YTD3.57%
Dividend2.28 P/FCF15.87 EPS past 5Y3.30% ROI9.40% 52W High-8.49% Beta0.44
Dividend %3.06% Quick Ratio1.30 Sales past 5Y19.00% Gross Margin78.30% 52W Low14.65% ATR1.41
Employees32200 Current Ratio1.40 Sales Q/Q-3.50% Oper. Margin21.40% RSI (14)56.49 Volatility2.44% 1.95%
OptionableYes Debt/Eq1.20 EPS Q/Q8.50% Profit Margin14.30% Rel Volume0.97 Prev Close74.53
ShortableYes LT Debt/Eq1.13 EarningsFeb 02 BMO Payout67.90% Avg Volume9.00M Price74.52
Recom2.30 SMA202.58% SMA50-0.30% SMA2000.25% Volume8,726,268 Change-0.01%
Jan-17-23Initiated Cantor Fitzgerald Overweight $95
Nov-18-22Initiated Credit Suisse Neutral $78
Oct-10-22Downgrade Guggenheim Buy → Neutral
Sep-14-22Downgrade Berenberg Buy → Hold $82 → $76
Jun-03-22Downgrade Raymond James Outperform → Mkt Perform
Apr-06-22Resumed Morgan Stanley Underweight $64
Dec-17-21Initiated Goldman Buy $72
Dec-09-21Resumed Wells Fargo Equal Weight $58
Nov-19-21Initiated BMO Capital Markets Outperform $72
Nov-01-21Downgrade Argus Buy → Hold
Show Previous Ratings
Feb-07-23 02:48PM
Feb-06-23 01:00PM
12:41PM
09:00AM
Feb-04-23 09:26AM
07:14AM Loading…
07:14AM
Feb-03-23 09:11AM
06:59AM
Feb-02-23 04:11PM
02:59PM
02:00PM
12:58PM
11:00AM
10:58AM
10:55AM
10:52AM Loading…
10:52AM
09:05AM
08:55AM
08:15AM
07:20AM
07:00AM
06:59AM
06:59AM
Feb-01-23 10:44AM
Jan-31-23 10:01AM
Jan-29-23 08:53AM
Jan-27-23 05:45PM
11:28AM
10:00AM
07:05AM
06:59AM Loading…
06:59AM
Jan-26-23 10:01AM
08:00AM
06:59AM
Jan-25-23 09:37AM
Jan-24-23 12:15PM
Jan-23-23 05:50PM
Jan-19-23 12:55PM
10:20AM
08:30AM
05:49AM
Jan-17-23 05:50PM
07:30AM
Jan-14-23 10:03AM
08:00AM
Jan-13-23 12:42PM
08:19AM
05:00AM
Jan-12-23 10:16AM
09:40AM
Jan-11-23 07:50AM
Jan-10-23 06:30PM
05:50PM
07:00AM
Jan-09-23 08:44AM
Jan-06-23 06:26PM
09:00AM
06:00AM
Jan-05-23 03:35PM
09:00AM
Jan-04-23 10:07AM
09:00AM
Jan-03-23 07:36PM
05:50PM
12:10PM
07:05AM
06:59AM
Jan-02-23 08:50AM
Dec-31-22 08:00AM
Dec-30-22 05:30AM
Dec-28-22 05:50PM
Dec-27-22 06:00PM
08:38AM
06:00AM
Dec-26-22 09:00AM
Dec-23-22 09:02AM
06:01AM
Dec-22-22 08:30AM
Dec-20-22 01:35PM
Dec-19-22 05:50PM
12:00PM
06:00AM
Dec-15-22 08:30AM
06:59AM
06:00AM
Dec-14-22 09:00AM
Dec-13-22 10:50AM
Dec-12-22 05:50PM
01:19PM
06:59AM
04:30AM
Dec-11-22 06:01AM
Dec-09-22 01:25PM
09:40AM
Dec-08-22 04:16PM
Dec-07-22 09:46AM
09:00AM
07:00AM
Dec-06-22 10:15AM
Dec-03-22 09:00AM
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Meyers Gregory ScottEVP, Chief Digital & Tech Off.Feb 01Option Exercise0.002,54302,543Feb 03 07:18 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerDec 02Option Exercise0.002,637044,603Dec 06 07:32 PM
Elkins David VEVP, Chief Financial OfficerDec 02Option Exercise0.008,7920128,578Dec 06 06:44 PM
VESSEY RUPERTEVP, Research & Early Dev.Dec 02Option Exercise0.008,792065,871Dec 06 06:43 PM
Powell AnnEVP, Chief Human ResourcesNov 09Sale80.4516,2501,307,31234,226Nov 14 06:57 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 07Option Exercise58.3152,6043,067,529102,989Nov 09 08:38 PM
VESSEY RUPERTEVP, Research & Early Dev.Nov 07Sale78.8845,9103,621,38157,079Nov 09 08:38 PM
Caforio GiovanniBoard Chair and CEOSep 20Sale69.7125,0001,742,750476,104Sep 22 05:12 PM
Caforio GiovanniBoard Chair and CEOSep 15Sale71.8450,0003,592,000501,104Sep 16 05:12 PM
Powell AnnEVP, Chief Human ResourcesSep 14Sale70.7525,0001,768,75050,476Sep 15 07:29 PM
Elkins David VEVP, Chief Financial OfficerSep 13Option Exercise48.49123,2775,977,702223,737Sep 15 07:29 PM
Elkins David VEVP, Chief Financial OfficerSep 13Sale71.30133,9519,551,167100,460Sep 15 07:29 PM
Weese MichelleEVP, Corporate AffairsJul 01Option Exercise0.001,88501,885Jul 05 04:29 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Jul 01Option Exercise0.009,356026,078Jul 05 04:28 PM
Caforio GiovanniBoard Chair and CEOJun 13Sale74.0430,0002,221,200551,104Jun 14 05:58 PM
LEUNG SANDRAEVP, General CounselJun 06Sale74.8965,0004,867,850308,627Jun 07 05:49 PM
Haller Julia ADirectorJun 03Option Exercise0.002,949013,619Jun 07 05:50 PM
Mily ElizabethEVP, Strategy & BDApr 01Option Exercise0.006,347012,481Apr 04 06:13 PM
Caforio GiovanniBoard Chair and CEOMar 21Sale71.5225,0001,788,000581,524Mar 23 07:43 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 16Option Exercise57.0047,3052,696,61293,613Mar 18 05:50 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 16Sale69.2574,5595,162,97346,308Mar 18 05:50 PM
Santiago Karen MurphySVP & ControllerMar 14Sale69.196,577455,09616,704Mar 16 07:32 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 14Sale69.2029,5322,043,52641,966Mar 16 07:32 PM
Caforio GiovanniBoard Chair and CEOMar 10Option Exercise0.00239,5010653,392Mar 14 09:20 PM
LEUNG SANDRAEVP, General CounselMar 10Option Exercise0.0060,2730388,747Mar 14 09:20 PM
Elkins David VEVP, Chief Financial OfficerMar 10Option Exercise0.0016,0670134,133Mar 14 09:18 PM
BOERNER CHRISTOPHER S.EVP, Chief Commercial OfficerMar 10Option Exercise0.0051,715081,649Mar 14 09:19 PM
Powell AnnEVP, Chief Human ResourcesMar 10Option Exercise0.0035,686078,829Mar 14 09:17 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 10Option Exercise0.0015,247081,213Mar 14 09:16 PM
Santiago Karen MurphySVP & ControllerMar 10Option Exercise0.0011,073024,489Mar 14 09:16 PM
Hirawat SamitEVP,Chief Med.Offr.,Drug Dev.Mar 10Option Exercise0.009,074018,953Mar 14 09:17 PM
Mily ElizabethEVP, Strategy & BDMar 10Option Exercise0.004,00508,246Mar 14 09:16 PM
Elkins David VEVP, Chief Financial OfficerMar 01Option Exercise0.0024,5770132,034Mar 03 05:33 PM
VESSEY RUPERTEVP, Research & Early Dev.Mar 01Option Exercise0.0023,350079,587Mar 03 05:33 PM
Caforio GiovanniBoard Chair and CEOFeb 24Sale67.0030,0002,010,000453,455Feb 28 04:44 PM